| Objective: To evaluate the clinical efficiency and adverse drug reaction (ADR) of Shua- nghuanglian (SHL) powder injection in the treatment of children's acute bronchopneumonia.Methods: 658 hospitalized pediatric patients with acute bronchopneumonia at the First Affiliated Hospital of Fujian Medical University from Jan. 2008 to Sept. 2010 were divided into two groups. The case group (n=321) was given both antibiotic and support treatment acc- ording to children's age, condition and laboratory test results, and was treated with SHL powder injection with intravenous does of 60mg/(kg.d). But the control group (n=337) used the same antibiotic and support treatment alone. Main outcome measures: cure rate, hospital stay, fever time, ADR rate, etc. Use SPSS 13.0 software for statistical analysis.Results: Of 658 children investigated, 439 were cured, 165 were improved. No one was ineffective and no one died. The cure rate was 76.0% for the case group and 73.9% for the control group. Difference between the two groups was not statistically significant (p=0.524). We used time-effect analysis to evaluate the clinical efficiency of SHL injection by Kaplan- Meier assay. The hospital stay [mean (standard error), (x|—)( Sx|—)] in the case group and the cont- rol group was 7.1(0.2) days and 8.4(0.2) days. The fever time in hospital was 2.3(0.2) days and 3.3(0.2) days. The total duration of sickness was 13.4(0.5) days and 14.5(0.5) days. The total fever time was 6.1(0.4) days and 7.1(0.4) days. All the differences between the two groups were statistically significant. 41 (6.2%) patients had ADR. The case group accounted for 24 (7.5%) while the control group accounted for 17 (5.0%). No statistical significance.Conclusions: The combination of SHL powder injection and antibiotic is effective and safe in the treatment of children's acute bronchopneumonia. Compared with using antibiotic alone, it can shorten hospital stay. Even more, it hasn't obvious difference on ADR. |
PDF Full Text Request